Identifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM)

Date

21 Dec 2015

Session

Basic Science, biomarkers, new diagnostics and translational research

Presenters

Lisa Roberts-Rapp

Citation

Annals of Oncology (2015) 26 (suppl_9): 8-15. 10.1093/annonc/mdv518

Authors

L. Roberts-Rapp1, P. Ansell1, R. Kular2, M. Song2, I. Sokolova2, H.K. Gan3, K.P. Papadopoulos4, A.B. Lassman5, R. Merrell6, P. Kumthekar7, A.M. Scott3, E. Gomez8, J. Fischer8, A. Bhathena1, K. Holen9, R. Lai9, D. Reardon10, M. van den Bent11

Author affiliations

  • 1 Discovery - Oncology, AbbVie Inc., 60064 - North Chicago/US
  • 2 Research & Development, Abbott Molecular, Des Plaines/US
  • 3 Department Of Medical Oncology, Austin Health and Olivia Newton-John Cancer Research Institute, Melbourne/AU
  • 4 Clinical Research, South Texas Accelerated Research Therapeutics, San Antonio/US
  • 5 Department Of Neurology And Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York/US
  • 6 Kellogg Cancer Center, NorthShore University Health System, Evanston/US
  • 7 Department Of Neurology, Northwestern University, Chicago/US
  • 8 Clinical Operations - Oncology, AbbVie Inc., 60064 - North Chicago/US
  • 9 Oncology Development, AbbVie Inc., 60064 - North Chicago/US
  • 10 Department Of Medical Oncology, Dana-Farber Cancer Institute, Boston/US
  • 11 Department Of Neurology/neurooncology, Erasmus MC Cancer Centre, Rotterdam/NL
More

Aim/Background

Aberrant EGFR signaling plays a vital role in GBM oncogenesis. ABT-414 comprises an EGFR-targeted antibody conjugated to the toxic agent monomethylauristatin F. An open-label, 3-arm, phase I study (NCT01800695) is underway to evaluate 3 different ABT-414 regimens in GBM. To understand the population most suited for ABT-414 therapy, assays measuring EGFR gene amplification/protein overexpression, and the presence of EGFRvIII mutation have been developed.

Methods

Total EGFR and EGFRvIII expression were measured with reverse transcription-polymerase chain reaction (RT-PCR). EGFR gene amplification was detected with fluorescence in situ hybridization (FISH) using 2 probes: Vysis locus-specific identifier EGFR probe and Vysis chromosome enumeration probe (CEP) 7 probe. FISH utilized Ratio of EGFR to CEP 7 to identify locus-specific EGFR gene amplification. Total EGFR protein expression was analyzed via immunohistochemical (IHC) using Dako pharmDx™ IHC assay. Relative expression of total EGFR and presence of EGFRvIII mRNA were determined with quantitative RT-PCR. Tumor tissues from 89 pts were used for these tests.

Results

IHC and RT-PCR confirmed expression of EGFR mRNA and protein are correlated in GBM tissue samples (Spearman correlation is –0.86, P = 0.0026). A strong association between EGFR gene amplification and mRNA overexpression was observed. EGFRvIII mRNA was detected almost exclusively in cases with EGFR amplification. Thus far, EGFR amplification has been confirmed in 23/29 pts tested. All 6/6 pts with confirmed objective radiographic responses by Response Assessment in Neuro-Oncology criteria displayed EGFR gene amplification, whereas only 5/6 pts had total EGFR mRNA overexpression using RT-PCR. EGFRvIII expression by RT-PCR was detected in 4/6 pts.

Conclusions

Assays were developed to characterize EGFR gene amplification, EGFR mRNA and protein expression, EGFRvIII status, and used to characterize EGFR status of GBM samples from pts treated with ABT-414 in ongoing phase I trial. When comparing EGFR status to pt outcome, EGFR amplification by FISH had strongest association with objective radiographic responses.

Clinical trial identification

NCT01800695

Disclosure

L. Roberts-Rapp, P. Ansell, R. Kular, M. Song, I. Sokolova, E. Gomez, J. Fischer, A. Bhathena, K. Holen, R. Lai: employee of AbbVie Inc. and may have stock/stock options. H.K. Gan: employee of Ludwig Institute for Cancer Research (licensed ABT-806). K.P. Papadopoulos: Corporate-sponsored Research from Abbvie, Medimmune, Daiichi, GSK, Onyx, Sanofi, and Novartis. A.B. Lassman: consultant for Impact Communications, Heron, Saatchi & Saatchi, Foundation Medicine, Biolumina, Genentech, Midatech, Celgene, Novartis, Defined Health, and Cutting Edge Information. A.M. Scott: consultant and stock ownership Life Science Pharmaceuticals. D. Reardon: speaker's bureau Merck/Schering and Genentech/Roche. M. van den Bent: Advisory Board: M. van den Bent – Roche, Celldex, Acetlion, Merck Ag, Cavion, and Novocure. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings